Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Regen BioPharma (RGBP) over the last 11 years, with Q4 2025 value amounting to $4578.0.

  • Regen BioPharma's Cash & Equivalents rose 329111.11% to $4578.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4578.0, marking a year-over-year increase of 329111.11%. This contributed to the annual value of $69555.0 for FY2025, which is 961438.55% up from last year.
  • Per Regen BioPharma's latest filing, its Cash & Equivalents stood at $4578.0 for Q4 2025, which was up 329111.11% from $69555.0 recorded in Q3 2025.
  • Regen BioPharma's 5-year Cash & Equivalents high stood at $727162.0 for Q3 2021, and its period low was $135.0 during Q4 2024.
  • In the last 5 years, Regen BioPharma's Cash & Equivalents had a median value of $69555.0 in 2025 and averaged $118886.3.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 9989.16% in 2024, then surged by 961438.55% in 2025.
  • Regen BioPharma's Cash & Equivalents (Quarter) stood at $353492.0 in 2021, then plummeted by 88.47% to $40741.0 in 2022, then surged by 205.58% to $124497.0 in 2023, then tumbled by 99.89% to $135.0 in 2024, then skyrocketed by 3291.11% to $4578.0 in 2025.
  • Its Cash & Equivalents was $4578.0 in Q4 2025, compared to $69555.0 in Q3 2025 and $1761.0 in Q2 2025.